MXPA03007092A - Nueva formulacion de liberacion modificada. - Google Patents

Nueva formulacion de liberacion modificada.

Info

Publication number
MXPA03007092A
MXPA03007092A MXPA03007092A MXPA03007092A MXPA03007092A MX PA03007092 A MXPA03007092 A MX PA03007092A MX PA03007092 A MXPA03007092 A MX PA03007092A MX PA03007092 A MXPA03007092 A MX PA03007092A MX PA03007092 A MXPA03007092 A MX PA03007092A
Authority
MX
Mexico
Prior art keywords
matrix former
formulation
unit dosage
water
drug substance
Prior art date
Application number
MXPA03007092A
Other languages
English (en)
Inventor
Anne Juppo
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0100477A external-priority patent/SE0100477D0/xx
Priority claimed from SE0100478A external-priority patent/SE0100478D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MXPA03007092A publication Critical patent/MXPA03007092A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MXPA03007092A 2001-02-13 2002-02-08 Nueva formulacion de liberacion modificada. MXPA03007092A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0100477A SE0100477D0 (sv) 2001-02-13 2001-02-13 Novel formulation
SE0100478A SE0100478D0 (sv) 2001-02-13 2001-02-13 Novel formulation
PCT/SE2002/000228 WO2002064121A1 (en) 2001-02-13 2002-02-08 Novel modified released formulation

Publications (1)

Publication Number Publication Date
MXPA03007092A true MXPA03007092A (es) 2003-11-18

Family

ID=26655389

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03007092A MXPA03007092A (es) 2001-02-13 2002-02-08 Nueva formulacion de liberacion modificada.

Country Status (19)

Country Link
US (3) US20040067252A1 (es)
EP (2) EP1361868A1 (es)
JP (2) JP2004518709A (es)
KR (1) KR20040058103A (es)
CN (2) CN1491104A (es)
AT (1) ATE324871T1 (es)
AU (1) AU2002228579B2 (es)
BR (1) BR0206825A (es)
CA (2) CA2434835A1 (es)
DE (1) DE60211130T2 (es)
DK (1) DK1368006T3 (es)
ES (1) ES2261643T3 (es)
HK (1) HK1059740A1 (es)
IL (1) IL157075A0 (es)
MX (1) MXPA03007092A (es)
NO (1) NO20033564L (es)
NZ (2) NZ526994A (es)
PT (1) PT1368006E (es)
WO (2) WO2002064121A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
JP2006517182A (ja) * 2002-09-28 2006-07-20 マクニール−ピーピーシー・インコーポレイテッド ２つのコア及び開口部を備えた加減放出型投薬形態
SE0301904D0 (sv) 2003-06-26 2003-06-26 Astrazeneca Ab Novel imidazopyridine compound II with therapeutic effect
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
JP2007507425A (ja) * 2003-08-29 2007-03-29 ダイノゲン ファーマシューティカルズ，インコーポレイテッド 胃腸管運動障害を処置するために有用な組成物
WO2005053652A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
AU2004294813A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
CA2549225A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride
SE0303451D0 (sv) * 2003-12-18 2003-12-18 Astrazeneca Ab New compounds
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
PL2001445T3 (pl) 2006-03-16 2015-06-30 Euro Celtique Sa Farmaceutyczne sferoidy
AU2009221765B2 (en) 2008-03-05 2015-05-07 Vicus Therapeutics, Llc Compositions and methods for mucositis and oncology therapies
WO2011000126A1 (zh) * 2009-06-29 2011-01-06 Liu Yu 脂溶性药物组合物、制备方法及其用途
EP3296295A1 (en) 2009-08-07 2018-03-21 American Life Science Pharmaceuticals, Inc. Compositions and methods for treating beta-amyloid related diseases
US20130165880A1 (en) 2010-09-17 2013-06-27 David T. Amos Antimicrobial disposable absorbent articles
WO2012070030A1 (en) * 2010-11-26 2012-05-31 University Of The Witwatersrand, Johannesburg A pharmaceutical composition
WO2013090439A1 (en) * 2011-12-12 2013-06-20 Orbis Biosciences, Inc. Sustained release particle formulations of guaifenesin
EP4035683A1 (en) * 2011-12-12 2022-08-03 Adare Pharmaceuticals USA, Inc. Sustained release particle formulations
WO2017004398A1 (en) * 2015-06-30 2017-01-05 Kemin Industries, Inc. Encapsulated active ingredients for controlled enteric release
US9889120B2 (en) 2016-01-14 2018-02-13 Vicus Therapeutics, Llc Combination drug therapies for cancer and methods of making and using them
DE102017108054A1 (de) 2017-04-13 2018-10-18 Natura Werk Gebr. Hiller GmbH & Co. KG Essbare Zusammensetzung zur Verdauungsförderung
EP4151210A3 (en) 2020-01-10 2023-06-14 Harmony Biosciences, LLC Pyridine-carboline derivatives as mchr1 antagonists for use in therapy
WO2023184282A1 (en) * 2022-03-30 2023-10-05 Guizhou Sinorda Biomedicine Co., Ltd X842 formulation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE593354A (es) * 1959-02-18
HU198844B (en) * 1984-06-14 1989-12-28 Sandoz Ag Process for producing new galenic pharmaceutical composition ensuring retarded release of active ingredient
US4629621A (en) * 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US5015479A (en) * 1987-02-02 1991-05-14 Seamus Mulligan Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine
US4956182A (en) * 1989-03-16 1990-09-11 Bristol-Myers Company Direct compression cholestyramine tablet and solvent-free coating therefor
US5405617A (en) * 1991-11-07 1995-04-11 Mcneil-Ppc, Inc. Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
US5433951A (en) * 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
NZ270439A (en) * 1995-02-02 1996-04-26 Bernard Charles Sherman Solid slow release pharmaceutical composition: carrier is polyethylene glycol and hydrophilic gel-forming polymer
US5851555A (en) * 1997-08-15 1998-12-22 Fuisz Technologies Ltd. Controlled release dosage forms containing water soluble drugs
SE9801526D0 (sv) * 1998-04-29 1998-04-29 Astra Ab New compounds
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions

Also Published As

Publication number Publication date
US20040067256A1 (en) 2004-04-08
NO20033564L (no) 2003-10-02
CN1491104A (zh) 2004-04-21
WO2002064118A1 (en) 2002-08-22
JP2004518708A (ja) 2004-06-24
NO20033564D0 (no) 2003-08-12
IL157075A0 (en) 2004-02-08
CA2434835A1 (en) 2002-08-22
NZ526993A (en) 2005-01-28
ATE324871T1 (de) 2006-06-15
US20080118560A1 (en) 2008-05-22
BR0206825A (pt) 2004-02-25
DK1368006T3 (da) 2006-07-24
PT1368006E (pt) 2006-08-31
EP1368006B1 (en) 2006-05-03
CN1491105A (zh) 2004-04-21
KR20040058103A (ko) 2004-07-03
ES2261643T3 (es) 2006-11-16
AU2002228579B2 (en) 2006-07-27
DE60211130T2 (de) 2006-11-30
JP2004518709A (ja) 2004-06-24
US20040067252A1 (en) 2004-04-08
NZ526994A (en) 2005-01-28
HK1059740A1 (en) 2004-07-16
DE60211130D1 (de) 2006-06-08
EP1368006A1 (en) 2003-12-10
WO2002064121A1 (en) 2002-08-22
CA2434542A1 (en) 2002-08-22
EP1361868A1 (en) 2003-11-19

Similar Documents

Publication Publication Date Title
HK1059740A1 (en) Novel modified released formulation
JP3805797B2 (ja) Ｎ−ピペリジノ−３−ピラゾールカルボキサミド誘導体、その塩およびそれらの溶媒和物の経口投与用医薬組成物
US6531153B2 (en) Composition with sustained release of levodopa and carbidopa
US6635278B1 (en) Pharmaceutical formulations
WO2004012700A3 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
KR101444979B1 (ko) 생체 이용율이 개선된 엔타카폰, 레보도파 및 카르비도파의 약학 조성물
DK170793B1 (da) Dispergerbar lægemiddelformulering og fremgangsmåde til fremstilling heraf
KR20180109992A (ko) Jak 키나아제 억제제 또는 약학적으로 허용가능한 그의 염을 함유하는 약학적 조성물
US6833478B2 (en) N,N-dinitramide salts as solubilizing agents for biologically active agents
CA2623018A1 (en) Pharmaceutical compositions of telmisartan
DK1113787T3 (da) Agitationsuafhængige farmaceutiske multipelenhedsretardformuleringer og fremgangsmåde til deres fremstilling
CZ2001792A3 (cs) Farmaceutická kompozice obsahující entakapon a nitakapon a zesíťovaný derivát celulózy
CA2067733C (en) Process for the preparation of a tablet or dragee composition containing a heat-, light- and moisture-sensitive active ingredient having monoclinic crystal structure
CA2435714C (en) Fenofibrate tablets
AU759869B2 (en) Pharmaceutical formulations
CA2364226A1 (en) Controlled-release compositions of betahistine
KR19990023194A (ko) 라세미화 반응에 대하여 안정화된 실란세트론 제제
KR100884685B1 (ko) 신속 방출 활성 물질을 함유하는 초순도 플루다라 경구제제
CA2520813A1 (en) Sustained release formulations of alkylene dioxybenzene derivatives useful as 5-ht1a agonists

Legal Events

Date Code Title Description
FG Grant or registration